News Snapshot:
Chinese researchers are conducting a trial to see if mixing Covid-19 vaccines that use different technologies is safe and whether it could boost immunity. A trial began earlier this month to give a first dose of the adenovirus-vectored vaccine made by CanSino Biologics, followed by a protein subunit vaccine produced by Anhui Zhifei Longcom Biopharmaceutical, according to a clinical trials registration site run by a department under the US National Institutes of Health. The Jiangsu Centre for Disease Control and Prevention is conducting the trial, with 120 people taking part in the eastern province, and they expect preliminary results in...
